全文获取类型
收费全文 | 76503篇 |
免费 | 44842篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 1498篇 |
儿科学 | 4421篇 |
妇产科学 | 608篇 |
基础医学 | 15908篇 |
口腔科学 | 5095篇 |
临床医学 | 12799篇 |
内科学 | 23448篇 |
皮肤病学 | 7606篇 |
神经病学 | 13644篇 |
特种医学 | 2238篇 |
外科学 | 14199篇 |
综合类 | 38篇 |
一般理论 | 22篇 |
预防医学 | 4316篇 |
眼科学 | 1278篇 |
药学 | 5687篇 |
中国医学 | 1016篇 |
肿瘤学 | 7546篇 |
出版年
2023年 | 52篇 |
2022年 | 41篇 |
2021年 | 1295篇 |
2020年 | 5086篇 |
2019年 | 10869篇 |
2018年 | 10130篇 |
2017年 | 11482篇 |
2016年 | 12136篇 |
2015年 | 12002篇 |
2014年 | 11893篇 |
2013年 | 12444篇 |
2012年 | 4351篇 |
2011年 | 4321篇 |
2010年 | 9054篇 |
2009年 | 5440篇 |
2008年 | 2330篇 |
2007年 | 1249篇 |
2006年 | 1235篇 |
2005年 | 1054篇 |
2004年 | 1010篇 |
2003年 | 909篇 |
2002年 | 926篇 |
2001年 | 581篇 |
2000年 | 405篇 |
1999年 | 88篇 |
1998年 | 95篇 |
1997年 | 85篇 |
1996年 | 72篇 |
1995年 | 79篇 |
1994年 | 70篇 |
1993年 | 44篇 |
1992年 | 48篇 |
1991年 | 39篇 |
1990年 | 46篇 |
1989年 | 39篇 |
1988年 | 36篇 |
1987年 | 30篇 |
1986年 | 21篇 |
1985年 | 22篇 |
1984年 | 20篇 |
1983年 | 20篇 |
1982年 | 26篇 |
1981年 | 10篇 |
1980年 | 23篇 |
1979年 | 17篇 |
1978年 | 15篇 |
1977年 | 10篇 |
1975年 | 13篇 |
1974年 | 12篇 |
1971年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
3.
Mohammad Javad Alemzadeh‐Ansari Ali Sarreshtehdari Seifollah Abdi Jamal Moosavi Omid Shafe Parham Sadeghipour Hamidreza Pouraliakbar Bahram Mohebbi 《Seminars in dialysis》2021,34(1):89-93
A 70‐year‐old man with a history of coronary artery bypass grafting 15 years back and arteriovenous (AV) fistula creation in the left arm 1 month back presented with acute coronary syndrome (ACS). He had not received dialysis before his referral. We felt the most likely etiology for these complaints was increased cardiac oxygen demand from an increased cardiac output related to the newly formed left AV fistula. Coronary angiography was done to detect any significant stenosis in the native or grafted vessels. This revealed that the left subclavian artery was totally occluded in the ostioproximal segment and the coronary arteries did not have occlusions to explain the ACS setting. CT angiography confirmed the angiographic findings of the totally occluded left subclavian artery followed by a well‐developed and patent left internal mammary artery to left anterior descending artery. This led to the consideration of a steal syndrome from the coronary artery by the subclavian artery distal to the occlusion. A successful percutaneous endovascular intervention on the left subclavian artery occlusion was performed. Subsequently, the patient became asymptomatic and experienced a dramatic increase in left ventricular ejection fraction. 相似文献
4.
Monica Poiani Myriam Labopin Giorgia Battipaglia Dietrich W. Beelen Johanna Tischer Jürgen Finke Arne Brecht Edouard Forcade Arnold Ganser Jakob R. Passweg Helene Labussiere‐Wallet Ibrahim Yakoub‐Agha Kerstin Schfer‐Eckart Nicolaus Kroeger Blandine Guffroy Annalisa Ruggeri Jordi Esteve Arnon Nagler Mohamad Mohty 《American journal of hematology》2021,96(1):40-50
Karyotypic analysis at time of diagnosis has an important value in determining initial response to treatment, remission duration and overall survival (OS) in acute myeloid leukemia (AML). Less is known about its value before allogeneic hematopoietic cell transplantation (allo‐HCT) in patients transplanted with active disease, either relapsed or primary refractory (Rel‐Ref) AML. We explored the impact of cytogenetic risk (stratification according to MRC‐UK) in 2089 patients with either Ref (n = 972) or Rel AML (n = 1117) transplanted during the period 2000‐2017. Overall, 154 patients had a favorable risk, 1283 had an intermediate risk and 652 had an adverse cytogenetic risk. Median follow‐up was 49 months. Compared to the favorable risk group, intermediate and adverse risk patients were associated with worse leukemia‐free survival and OS and also with a higher incidence of relapse. In a subgroup analysis of patients in the intermediate risk group harboring Fms‐like tyrosine kinase 3‐internal tandem duplication (FLT3‐ITD), this remained an important prognostic factor, being associated with worse outcomes. When analyzing patients according to the intensity of the conditioning regimen, no differences were observed for the main transplant outcomes. In conclusion, in patients diagnosed with AML and transplanted with active disease, karyotype remains an important prognostic factor, allowing splitting patients into different risk groups according to their cytogenetics. Similarly, FLT3‐ITD mutation also remains a negative prognostic factor in this population. 相似文献
5.
6.
7.
8.
Andreas Glenthj Lasse H. Jakobsen Henrik Sengelv Syed A. Ahmad Kristian Qvist Annika Rewes Christian B. Poulsen Ulrik M. Overgaard Ingolf Mlle Marianne T. Severinsen Casper N. Strandholdt Jack Maibom Annette R. Kodahl Jesper Ryg Pernille Ravn Isik S. Johansen Sren N. Hels Sren Jensen‐Fangel Jacek Kisielewicz Lothar Wiese Marie Helleberg Ole Kirk Michael R. Clausen Henrik Frederiksen 《European journal of haematology》2021,106(1):72-81
9.
Hendrik Kröning Thomas Göhler Thomas Decker Marc Grundeis Georgi Kojouharoff Jörg Lipke Dieter Semsek Enno Moorahrend Annette Sauer Harald-Robert Bruch Rüdiger Liersch Arnd Nusch Ursula Vehling-Kaiser Manfred Welslau Ralf Grunewald Hanns-Detlev Harich Marcel Stephany Jens Uhlig Rebecca de Buhr Melanie Frank Cathrin Hogrefe Norbert Marschner Karin Potthoff Frank Hartmann Timo Reisländer Ingo Schwaner 《International journal of cancer. Journal international du cancer》2023,153(6):1227-1240
The prospective, multicenter, noninterventional TACTIC study assessed effectiveness and safety of trifluridine/tipiracil (FTD/TPI) in patients with metastatic colorectal cancer (mCRC) in a real-world setting in Germany, thus evaluating the external validity of the findings from the pivotal RECOURSE trial. Primary endpoint was overall survival (OS). Secondary objectives included progression-free survival (PFS), safety, and quality of life (QoL). Subgroups comprised patients with good (<3 metastatic sites at inclusion, ≥18 months from diagnosis of first metastasis to inclusion) or poor (remaining patients) prognostic characteristics (GPC/PPC). GPC without liver metastases was considered best prognostic characteristics (BPC). In total, 307 eligible patients (pretreated or not suitable for other available therapies) were treated with FTD/TPI. Overall, median [95%-CI] OS was 7.4 months [6.4-8.6], median PFS was 2.9 months [2.8-3.3]. In BPC (n = 65) and GPC (n = 176) compared to PPC (n = 124) subgroup, median OS (13.3 [9.1-17.6] vs 8.9 [7.6-9.8] vs 5.1 [4.4-7.0] months) and median PFS (4.0 [3.3-5.3] vs 3.4 [3.0-3.7] vs 2.6 [2.4-2.8] months) were longer. Patient-reported QoL, assessed by validated questionnaires (EQ-5D-5L, PRO-CTCAE), was stable throughout FTD/TPI treatment. Predominant FTD/TPI-related adverse events of grades 3 or 4 were neutropenia (13.0%), leukopenia (7.5%), and anemia (5.2%). Altogether, palliative FTD/TPI therapy in patients with pretreated mCRC was associated with prolonged survival, delayed progression, maintained health-related QoL, and manageable toxicity. Low metastatic burden and indolent disease were favorable prognostic factors for survival. TACTIC confirms the effectiveness and safety of FTD/TPI, highlighting its value in routine clinical practice. 相似文献
10.